BioCentury | Jan 22, 2009
Targets & Mechanisms

A niche play for stem cells

...out of the bones and into the blood. A recombinant form of SCF called Stemgen ancestim...
...adjuvant to Neupogen-mediated mobilization prior to autologous peripheral blood progenitor cell transplantation. Biovitrum AB acquired Stemgen...
BioCentury | Dec 22, 2008
Company News

Amgen, Biovitrum deal

...Biovitrum completed its previously announced acquisition of Amgen's marketed products Kepivance palifermin and Stemgen ancestim for...
BioCentury | Sep 22, 2008
Company News

Amgen, Biovitrum deal

...Biovitrum will acquire marketed products Kepivance palifermin and Stemgen ancestim from Amgen. The deal also includes...
...mucositis in patients with hematologic malignancies receiving myeltoxic therapy requiring hematopoietic stem cell support, while Stemgen...
BioCentury | Sep 22, 2008
Finance

Shaking in their shorts

...to SEK61 last week on news it will acquire marketed products Kepivance palifermin and Stemgen ancestim...
BioCentury | Sep 22, 2008
Strategy

Global reinvention

...first chance to market products globally. Biovitrum will acquire Amgen's marketed Kepivance palifermin and Stemgen ancestim...
...oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support. Stemgen...
...for royalties on these improvements in undisclosed indications. Biovitrum has no such financial obligations for Stemgen...
BioCentury | Sep 16, 2008
Company News

Biovitrum in deal for three Amgen drugs

...Biovitrum (SSE:BVT) will acquire marketed products Kepivance palifermin and Stemgen ancestim from Amgen (NASDAQ:AMGN). The deal...
...mucositis in patients with hematologic malignancies receiving myelotoxic therapy requiring hematopoietic stem cell support, while Stemgen...
BioCentury | Jul 26, 1999
Finance

Value ranking

...III I Novantrone I I Nuvance I Mobist II Compound Reg III II Neupogen I Stemgen...
BioCentury | Apr 5, 1999
Finance

1Q Market Review: Divergence of big & small

...expecting FDA approvals for Agenerase HIV protease inhibitor from Vertex Pharmaceuticals Inc. (VRTX, Cambridge, Mass.), Stemgen...
BioCentury | Sep 14, 1998
Tools & Techniques

AMGN's product portfolio

...cells Marketed Neupogen G-CSF Stimulate white blood cells Marketed Infergen consensus interferon Hepatitis C Marketed Stemgen...
BioCentury | Sep 14, 1998
Tools & Techniques

Amgen lays MGDF to rest

...addition to its line of internally developed products. Advanced products remaining in its pipeline are Stemgen...
Items per page:
1 - 10 of 19